If you're looking to shake things up in the new year, these streaming platforms will help you diversify your music-listening ...

WARMINSTER, Pa. (AP) — WARMINSTER, Pa. (AP) — Arbutus Biopharma Corp. (ABUS) on Thursday reported a loss of $7.7 million in its third quarter. The Warminster, Pennsylvania-based company said it had a ...

Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a ...

Arbutus Biopharma (ABUS) is a clinical-stage biotech focused on LNP technology, with value now hinging on ongoing patent litigation against Moderna and Pfizer/BioNTech. Recent management changes and ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from Arbutus ...

WARMINSTER, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...

Arbutus Biopharma had made no secret of its plans to step up its work on imdusiran. Now, the company has regained the China rights to the potential functional cure for hepatitis B. China-based Qilu ...

WARMINSTER, Pa. - Arbutus Biopharma Corporation (NASDAQ:ABUS), currently valued at $645 million, has regained full global rights to its lead hepatitis B compound imdusiran after mutually agreeing with ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The end of the deal, which ...

Tornadoes: A couple are possible. Hail: Isolated hail up to ping pong ball size. Wind: Gusts up to 65 mph possible. The watch covers more than 22 million people, including densely populated areas ...

Arbutus Biopharma Corporation announced promising data from a late-breaker poster presentation at the EASL Congress 2025, revealing that its treatment combining imdusiran, a RNAi therapeutic, with VTP ...